Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease

Certolizumab pegol (CZP), an anti–tumor necrosis factor α agent, is an effective therapy for Crohn's disease (CD). A population pharmacokinetic (PK) analysis of subcutaneously administered CZP was performed using data from 2157 CD patients from 9 separate studies. The aim was to determine which...

Descripción completa

Detalles Bibliográficos
Autores principales: Wade, Janet R., Parker, Gerry, Kosutic, Gordana, Feagen, Brian G., Sandborn, William J., Laveille, Christian, Oliver, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Pharmacometrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680228/
https://www.ncbi.nlm.nih.gov/pubmed/25735646
http://dx.doi.org/10.1002/jcph.491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680228/
https://www.ncbi.nlm.nih.gov/pubmed/25735646
http://dx.doi.org/10.1002/jcph.491

Ejemplares similares